ANDA 76265, held by Hikma Pharmaceuticals. Hydrochlorothiazide; Lisinopril.
As of Nov 21, 2026, ANDA 76265 (Lisinopril and Hydrochlorothiazide), held by Hikma Pharmaceuticals, was first approved by FDA on Jul 8, 2002, with 14 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 8, 2002 | Original application | Approved | None posted |
| Lisinopril and Hydrochlorothiazide12.5MG;10MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Discontinued |
| Lisinopril and Hydrochlorothiazide12.5MG;20MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Discontinued |
| Lisinopril and Hydrochlorothiazide25MG;20MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Discontinued |
| Aug 20, 2020 | Supplement 31Labeling · Standard review | Approved | None posted |
| Aug 3, 2020 | Supplement 30Labeling · Standard review | Approved | None posted |
| Aug 3, 2020 | Supplement 29Labeling · Standard review | Approved | None posted |
| May 26, 2015 | Supplement 26Labeling · Standard review | Approved | None posted |
| May 26, 2015 | Supplement 25Labeling · Standard review | Approved | None posted |
| May 26, 2015 | Supplement 24Labeling · Standard review | Approved | None posted |
| May 26, 2015 | Supplement 23Labeling · Standard review | Approved | None posted |
| Sep 11, 2013 | Supplement 20Labeling · Standard review | Approved | None posted |
| Sep 11, 2013 | Supplement 18Labeling | Approved | None posted |
| Sep 11, 2013 | Supplement 17Labeling | Approved | None posted |
| Mar 3, 2010 | Supplement 15Labeling | Approved | None posted |
| Mar 3, 2010 | Supplement 14Labeling | Approved | None posted |
| Apr 9, 2007 | Supplement 9Labeling | Approved | None posted |
| Aug 8, 2006 | Supplement 7Labeling | Approved | None posted |
| Jul 8, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters